HCC: Mechanistic Assessment Confirms Tremelimumab-Durvalumab Combination
hosted byProjects In Knowledge Inc. (PIK)HCC: Mechanistic Assessment Confirms Tremelimumab-Durvalumab Combination is organized by Projects In Knowledge Inc. (PIK).
Release Date: Feb 23, 2023
Termination Date: Feb 22, 2024
Activity Goal:
The goal of this program is to provide data from medical meetings, expert analysis insights on current and emerging management strategies, and interactive case studies based on the most up-to-date evidence-based medicine and clinical trial results in HCC.
Learning Objective(s):
• Evaluate the latest clinical trial data regarding novel tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), anti-vascular endothelial growth factor (VEGF) agents, and emerging combinations for the treatment of advanced HCC.
• Select appropriate treatment for patients with advanced HCC across multiple lines of therapy.
Additional details will be posted as soon as information is available
